We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 27, 2020

Ibrutinib Treatment for First-Line and Relapsed/Refractory CLL

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
Clin. Cancer Res 2020 Mar 24;[EPub Ahead of Print], JC Byrd, RR Furman, SE Coutre, IW Flinn, JA Burger, K Blum, JP Sharman, W Wierda, W Zhao, NA Heerema, Y Luan, EA Liu, JP Dean, S O'Brien

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading